Cellular Communicators

Exosomes are nanometer-sized membrane sacs, or vesicles, that are released and received by nearly all cells in the body. Acting as a cellular communication system, exosomes deliver various molecules – DNA, RNA, proteins and lipids – from cell to cell.

Exosome Biology

Unique protein and carbohydrate molecules on the surface of exosomes allow them to traffic in the body and be taken up efficiently by cells.
Upon delivery, the exosome’s cargo can change the biological function of the recipient cell according to the instructions encoded by the payload.
Exosomes do not randomly distribute, but rather appear to seek specific cellular targets. Directing their path to precise cells creates the powerful potential to deliver diverse therapies to intended targets, modulating cellular function to achieve therapeutic benefit

Two inherent characteristics of exosomes offer important opportunities for drug delivery: their membrane composition and immune-silent nature.

Membrane Composition

The complex membrane composition of exosomes allows them to deliver their biological messages and thus change the behavior of the recipient cells in two ways: by efficiently entering target cells or by interacting with proteins on the cell’s surface.

Immune Silent

Exosomes are, by their very nature, believed to evade the immune system, which allows exosomes to move through the various sensors the body uses to detect and halt the spread of foreign substances.

Therapeutic Messengers

Unlike liposomes and other lipid nanoparticles that seek to mimic nature, exosomes can be forward engineered to take advantage of their natural properties while being improved to deliver specific drug candidates.

Precision Engineered Exosomes

Codiak has created a proprietary platform for exosome design and manufacturing that allows for precise targeting of important molecular pathways, cells, and tissue types involved with human disease.

Engineering Exosomes

Codiak has developed the technology to engineer exosomes to express and deliver therapeutic drug candidates. Using our proprietary engEx™ Platform, we can effectively hijack this natural messenger system and dictate the messages that get delivered.
Using our technology, exosomes are either loaded with potent and specific payloads, or producing cells are programmed to secrete exosomes carrying therapeutic molecules on their surface or in their interior. These engineered messages become instructions for recipient cells.
Upon contact, engineered exosomes can change biological functions in recipient cells. Instructions encoded within the luminal cargo of the exosome are taken up into the cell cytosol. Instructions encoded in the exosome membrane are delivered via protein/protein interactions at the cell surface.

We are leveraging this versatile platform technology to develop a broad pipeline of product candidates with the potential to have a transformative impact on the treatment of a broad spectrum of diseases with high unmet medical need.

Publications & Presentations

November 18, 2019
Codak Biosciences | Reprogramming of tumor-associated M2 macrophages with antisense oligonucleotides-loaded exosomes results in potent single-agent antitumor activity

Codiak presented data at the American Association for Cancer Research’s Special Conference on Tumor Immunology and Immunotherapy demonstrating the potential of engineered exosomes incorporating an antisense oligonucleotide (ASO) to selectively reprogram tumor-associated macrophages and generate potent anti-tumor activity.

November 8, 2019
Codiak BioSciences | Selective Activation of Antigen Presenting Cells by exoSTING Enhances Tumor Antigen-Specific Immune Response

Codiak presented data at The Society for Immunotherapy of Cancer (SITC) demonstrating that exoSTING shows unique pharmacodynamic effects and tumor antigen-specific systemic immune responses compared to free STING agonist.

Codiak BioSciences | Exosome Surface Display of IL-12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared to Recombinant IL-12

Codiak presented data at The Society for Immunotherapy of Cancer (SITC) supporting that exoIL-12 demonstrates tumor-retained and dose-dependent pharmacology with superior anti-tumor efficacy compared to soluble recombinant IL-12.

April 29, 2019
Codiak BioSciences | Development of a platform for exosome engineering using a novel and selective scaffold protein for surface display

Codiak presented data supporting the identification of a novel and selective scaffold protein, PTGFRN, as part of its engEX exosome platform at the Annual Meeting of the International Society for Extracellular Vesicles (ISEV).

April 1, 2019
Codiak BioSciences | engEx™: A novel exosome engineering platform enabling targeted transfer of pharmacological molecules

Codiak presented data supporting the potential of its engEX™ Platform and its proprietary PTGFRN protein scaffold at the 2019 American Association for Cancer Research (AACR) Annual Meeting

March 13, 2019
Codiak BioSciences | Developing an Engineered Exosome Therapeutic Platform for Immuno-Oncology

Codiak presented preclinical data in support of its engEx Platform for engineering exosomes at the Keystone Symposium on Cancer Immunotherapy.

November 9, 2018
Codiak BioSciences | Selective delivery of exosome-mediated STING agonist to antigen presenting cells results in significantly improved potency and reduced toxicity

Codiak presented results from preclinical studies demonstrating the potential efficacy of exoSTING™, a novel engineered exosome product candidate targeting checkpoint refractory tumors at the Society for Immunotherapy of Cancer (SITC)’s 33rd Annual Meeting.